Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.

European journal of nuclear medicine and molecular imaging·2026
Same author

Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer.

Cancers·2026
Same author

Discriminating inflammation from malignancy with short-dynamic patlak parametric 18 F-FDG PET/CT.

European journal of nuclear medicine and molecular imaging·2026
Same author

Comparing Response Evaluation Methods for PRRT in Neuroendocrine Tumors: Insights from an Exploratory Study.

Cancers·2026
Same author

Added Value of SPECT/CT in Radio-Guided Occult Localization (ROLL) of Non-Palpable Pulmonary Nodules Treated with Uniportal Video-Assisted Thoracoscopy.

Journal of clinical medicine·2025
Same author

Primary Score as a Predictive Marker in Intermediate-Risk Prostate Cancer: Insights from PSMA PET/CT Imaging.

Nuclear medicine and molecular imaging·2025
Same journal

The diagnostic and predictive value of miR-145-3p in gastric cancer and its regulation of gastric cancer progression via targeting CREB1.

The International journal of biological markers·2026
Same journal

PFKP: A biomarker for prognosis, response to treatment and immune function of breast cancer.

The International journal of biological markers·2026
Same journal

Luminex assay of plasma IL-6, TNF-α, leptin, and adiponectin: Impact of anticoagulants, single-well analysis, and freeze-thaw stability.

The International journal of biological markers·2026
Same journal

Expression of concern: "RIPK4 is Downregulated in Poorly Differentiated Tongue Cancer and is Associated with Migration/Invasion and Cisplatin-Induced Apoptosis".

The International journal of biological markers·2026
Same journal

Association of NF-kappaBIA rs696 gene polymorphism with breast cancer risk in Bangladeshi women: A case-control study.

The International journal of biological markers·2026
Same journal

Circulating tumor cells and tumor-derived cell-free DNA in cancer management: Clinical evidence, limitations, and future directions.

The International journal of biological markers·2026
See all related articles

Related Experiment Video

Updated: Dec 28, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.8K

Molecular imaging and immunotherapy.

Laura Evangelista1,2

  • 1Nuclear Medicine Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

The International Journal of Biological Markers
|February 22, 2020
PubMed
Summary
This summary is machine-generated.

Positron emission tomography (PET) using 18F-Fluorodeoxyglucose (FDG) PET/CT is a valuable tool for assessing treatment response in patients undergoing immunotherapy for cancers like lymphoma, melanoma, and lung cancer.

Keywords:
FDGImmunotherapyPET/CTlung cancermelanoma

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.6K

Related Experiment Videos

Last Updated: Dec 28, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.8K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.6K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiology

Background:

  • Immunotherapy has revolutionized cancer treatment, but evaluating patient response remains challenging.
  • 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) is an imaging technique with potential in oncology.
  • Assessing treatment efficacy is crucial for optimizing patient management in immunotherapy.

Observation:

  • FDG PET/CT has shown utility in evaluating response to immunotherapy across various cancer types.
  • Clinical experiences highlight its use in lymphoma, malignant melanoma, and lung cancer.
  • The technique is being explored in different disease stages, including prediction and prognosis.

Findings:

  • FDG PET/CT can provide early insights into treatment response to immunotherapy.
  • Its application extends to predicting and monitoring prognosis in patients receiving immunotherapy.
  • Evidence suggests a significant role for FDG PET/CT in patient selection and management.

Implications:

  • FDG PET/CT may help personalize immunotherapy treatment strategies.
  • This imaging modality can aid in identifying patients who will benefit from immunotherapy.
  • Further research can refine the role of FDG PET/CT in clinical practice for immunotherapy.